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1Introduction
Cervical cancer is the second most common cancer and 
the third most common cause of cancer- related death in 
females worldwide. Most cervical cancers are squamous 
cell carcinomas. Adenocarcinoma of the uterine cervix 
accounts worldwide for 10–20% of all cervical cancers 
[1]. Adenocarcinoma in situ (AIS) of the uterine cervix 
is considered as a precancerous lesion of invasive cervical 
adenocarcinoma [2]. It has been shown that adenocarci-
noma, compared to squamous cell carcinoma with the 
same stage and tumor size, has a poorer prognosis due 
to a higher rate of metastases [3].
In high- income countries such as the USA and European 
countries, there is a trend of decreasing incidence of 
squamous cell carcinoma, but a relative and absolute 
increase in the incidence of adenocarcinoma of the uterine 
cervix [1, 4–7]. Most studies found that this increase was 
caused by an increasing incidence in younger women 
(under 55 years). In the Netherlands, similar trends in 
incidence of invasive cervical carcinomas were found. The 
incidence and mortality rates of squamous cell carcinoma 
have decreased in past decades [8] only to increase in 
the last decade [9]. The incidence of cervical adenocar-
cinoma remained relatively stable or increased, predomi-
nantly caused by an increasing incidence in younger women 
[8]. This differed for the precursor lesions as in 1987–2003 
a decreasing incidence of adenocarcinoma in situ (AIS) 
was found [10].
Because there are no recent rates for the Netherlands, 
the aim of this study was to explore the most recent 
incidence rates of AIS, adenocarcinoma, and squamous 
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Abstract
In the developed world, the incidence of cervical squamous cell carcinoma has 
decreased, however, the incidence of adenocarcinoma in situ (AIS) and invasive 
adenocarcinoma increased, predominantly in young females. The goal of this 
study was to evaluate the most recent incidence rates of AIS, adenocarcinoma, 
and squamous cell carcinoma of the uterine cervix in the Netherlands in 2004–
2013. By using Dutch national pathology and cancer registries, we calculated 
European standardized incidence rates (ESR) and estimated annual percentage 
changes (EAPC) for AIS during 2004–2013 and for invasive cervical carcinomas 
during 1989–2013. For AIS, presence or absence of concomitant cervical in-
traepithelial neoplasia (CIN) was explored. The estimated annual percentage 
change (EAPC) of squamous cell carcinoma decreased significantly in 1989–2013, 
predominantly in 1989–2003. The EAPC of invasive adenocarcinoma decreased 
in 1989–2003, but remained stable in 2004–2013. The EAPC of AIS increased 
significantly, predominantly in women of 25–39 years old. Of these AIS cases, 
58.9% had concomitant CIN and AIS with concomitant CIN showed a signifi-
cantly higher EAPC compared to AIS without CIN. Our conclusion is that 
despite a nationwide screening program for cancer of the uterine cervix, the 
incidence of adenocarcinoma in the Netherlands remained stable during 2004–
2013 and the incidence of adenocarcinoma in situ increased. This was most 
predominant in cases with concomitant CIN and in younger females. The in-
cidence of squamous cell carcinoma decreased in the same timeframe.
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cell carcinoma of the uterine cervix in the Netherlands. 
Changes in these rates can be an indication of alterations 
in underlying risk factors and/ or screening procedures. 
The correlation between AIS and the presence or absence 
of concomitant cervical intraepithelial neoplasia (CIN) was 
also investigated.
Methods
Data collection
Data concerning the incidence of adenocarcinoma, squa-
mous cell carcinoma, and other malignant cancers of the 
uterine cervix were obtained from the Netherlands national 
cancer registry (IKNL, www.cijfersoverkanker.nl). Cancers 
such as adenosquamous carcinoma, adenoid cystic carci-
noma, and small- cell carcinoma were grouped together 
and classified as “other” malignant cancers. Data covering 
the years 1989–2013 were collected. Data concerning the 
population size were retrieved from the website of Statistics 
Netherlands (statline.cbs.nl).
Since the national cancer registry only registers the 
invasive carcinomas, data concerning AIS had to be 
retrieved from “the nationwide network and registry of 
histo- and cytopathology in the Netherlands” (PALGA). 
In this nationwide network, excerpts of all histopathology 
and cytopathology reports are generated automatically at 
the pathology laboratories and transferred to a central 
database, with nationwide coverage from 1991 onwards 
[11]. Patients can object to the uptake of their informa-
tion in this database. The excerpts from the database 
comprise a free text field for the full conclusion and a 
SNOMED- like coded diagnosis line, describing the type 
of material and the histological diagnosis. Patients are 
identified through their birth date and the first eight let-
ters of their (maiden) family name. This identification 
code enables linkage of the patient’s tests, preventing 
double inclusion. Any request for information for scientific 
research from this database has to be approved by the 
Pathologisch Anatomisch Landelijk Geautomatiseerd 
Archief (PALGA) committee and information is coded 
so it is not directly convertible to specific patients. For 
the period 2004–2013, all histological records with “adeno-
carcinoma”, “adenocarcinoma in situ”, and/or “atypia” 
mentioned in the conclusion or diagnosis- line, combined 
with the term cervix, were selected. A total of 9900 records 
from 6138 patients were retrieved. These records were 
scrutinized for the actual presence of the diagnosis adeno-
carcinoma in situ, CGIN3 (cervical glandular intraepithelial 
neoplasia grade 3), and severe or high- grade atypia of 
the endocervical cylindrical cells. Patients were excluded 
if there was only information available concerning cytol-
ogy, when it was not clear if the lesion was glandular in 
origin, if there was only mild or moderate atypia of the 
endocervical cells, when the lesion was described as aden-
osquamous or when the lesion was not primarily cervical 
in origin, but for instance endometrial. Cases with (micro)
invasive growth were also excluded. Age was defined as 
the age at primary diagnosis of AIS. Furthermore, the 
presence of concomitant CIN, ranging from CIN1 to 
invasive squamous carcinoma was assessed. Data concern-
ing racial/ethnic groups are not available in the database, 
so we cannot comment on racial/ethnic differences.
Statistical analysis
Crude rates were calculated per 105 women years. For 
invasive carcinomas, absolute incidence rates from the 
national cancer registry were used. Age- adjusted rates were 
calculated for the European standard population per 105 
women years resulting in European Standardized Rates 
(ESR). The ESR was used to calculate the Estimated Annual 
Percentage Change (EAPC) by transforming all ESR into 
a natural logarithm (ln) and using calendar year as a 
regression variable to fit a regression line to the natural 
logarithms of the ESR using calendar year as independent 
variable. The formula that was used was y = mx + b, 
where y = ln(ESR) and x = calendar year. Then, EAPC 
equals 100*(em−1). The standard error is obtained from 
the fit of the regression line and used to calculate the 
95% confidence interval, again using the above mentioned 
formula. The null- hypothesis was that the slope of the 
curve is zero. The statistical difference of the incidence 
rates over time from the null- hypothesis was calculated 
using Pearson’s correlation coefficient with two- sided sig-
nificance. The differences in percentages and age for AIS 
with and without concomitant squamous lesions were 
calculated with t- test. All analysis was performed using 
IBM SPSS statistical software (version 20.0.01).
Results
Figure 1 shows the European standardized rates of the 
three different cervical cancer types and of all cervical 
cancer in the period 1989–2013. In Table 1, the estimated 
annual percentage change of the three subgroups and of 
all cervical cancer in the periods 1989–2013, 1989–2003, 
and 2004–2013 is shown. There was a significant decrease 
in the incidence of squamous cell carcinoma of the uterine 
cervix (r = −0.67; P = 0.00) with an EAPC of −0.90% 
(95% CI:−1.28, −0.51; P = 0.00) and of other cervical 
carcinomas (including adenosquamous carcinoma) 
(r = −0.84; P = 0.00) with an EAPC of −3.05% (95%CI: 
−3.81, −2.29; P = 0.00) in the Netherlands in the period 
1989–2013. This decrease in squamous cell carcinomas is 
predominantly caused by the age groups of 60+ years 
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(data not shown). The incidence of adenocarcinoma of 
the uterine cervix remained relatively stable (r = 0.27; 
P = 0.19) with an EAPC of 0.40% (95% CI: −0.19, 0.99; 
P = 0.21) in this same period. Overall, the incidence of 
cervical cancer decreased in 1989 to 2013 (r = −0.68; 
P = 0.00) with an EAPC of −0.90% (95% CI: −1.28, 
−0.51; P = 0.00). However, when the rates are subdivided 
into two time periods, the EAPC of all cancer types, 
including adenocarcinoma, was negative in 1989–2003, 
although the change is nonsignificant for this last group. 
During 2004–2013, the EAPC for all cancer types remained 
stable. All three cancer types show two peaks in incidence: 
the first at 35–39 years and the second at 70–74 years 
age (data not shown in figures).
After selection, a total of 1678 AIS patients were identi-
fied and included in this study. The mean incidence 
number of AIS over 10 years (2004–2013) was 167 cases 
per year and the mean ESR was 1.99 per 100,000 women 
years, compared to a mean ESR for adenocarcinoma of 
1.59. The European standardized incidence rates of AIS 
showed a significant increase (r = 0.95; P = 0.00) in the 
years 2004–2013 with an EAPC of 9.20% (95% CI: 7.50, 
10.92; P = 0.00) (Fig. 2 and Table 2). This increase is 
visible in the age groups from 25 up until 39 years 
(P = 0.00; Fig. 3). The crude and European standardized 
rates of adenocarcinoma in the years did not significantly 
increase in 2004 to 2013 (ESR: r = 0.33; P = 0.32) with 
an EAPC of 1.31 (95% CI: −0.66, 3.31; P = 0.24). In 
the 40+ age groups, the incidence of AIS showed only 
minor increment (r = 0.68; P = 0.03).
There were 989 patients with AIS and concomitant CIN 
(58.9% of all AIS patients) and 689 patients with AIS 
but without concomitant CIN (41, 1%; P = 0.00). The 
mean age of AIS patients with concomitant CIN [36.0 years 
[SD: 7.8]) is significantly lower compared to AIS patients 
without CIN (40.2 years [SD: 9.6]; [P = 0.00]). AIS with 
concomitant CIN showed a slightly stronger increment 
in ESR (r = 0.93; P = 0.00) and EAPC (10.96%; 95% 
CI: 8.38, 13.60; P = 0.00) as compared to the group 
without concomitant CIN (r = 0.93; P = 0.00), which 
had an EAPC in between the rates for AIS and invasive 
adenocarcinoma (6.93%; 95% CI: 5.06, 8.83; P = 0.00) 
(Fig. 4 and Table 2). The EAPC of AIS with concomitant 
CIN was comparable to the rate of all AIS cases. When 
the correlation of the ESR of AIS with time was adjusted 
for the presence of CIN, the correlation was not significant 
(r = 0.57; P = 0.11).
Discussion
The aim of this study was to explore the most recent 
incidence rates of cervical lesions in the Netherlands with 
emphasis on adenocarcinoma in situ. First we examined 
the European standardized incidence rates (ESR) and the 
estimated annual percentage change (EAPC) for invasive 
cancers and found that between 1989 and 2013 the inci-
dence of cervical cancer, predominantly squamous cell 
carcinoma significantly decreased. The incidence of invasive 
adenocarcinoma remained relatively stable. However, when 
Figure 1. Scatterplot of the European standardized rates (ESR) of all 
cervical cancer and the different cancer types with correlation line in the 
period 1989–2013. (Data extracted from www.cijfersoverkanker.nl).
year
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Table 1. EAPC, 95% confidence interval (95% CI) and P- value for SCC, ACA, other cervical carcinomas (other), and total cervical carcinomas (total) 
in the periods 1989–2013, 1989–2003, and 2004–2013. (Data extracted from www.cijfersoverkanker.nl).
1989–2013 1989–2003 2004–2013
EAPC (%) 95% CI (%) P- value EAPC (%) 95% CI (%) P- value EAPC (%) 95% CI (%) P- value
SCC −0.90 −1.28, −0.51 0.00 −2.57 −3.14, −1.99 0.00 0.20 −0.59, 0.99 0.56
ACA 0.40 −0.19, 0.99 0.21 −0.50 −1.66, 0.68 0.39 1.31 −0.66, 3.31 0.24
Other −3.05 −3.81, −2.29 0.00 −4.59 −6.26, −2.89 0.00 −0.60 −2.72, 1.57 0.61
Total −0.90 −1.28, −0.51 0.00 −2.47 −3.04, −1.89 0.00 0.30 −0.68, 1.29 0.49
EAPC, estimated annual percentage change; SCC, squamous cell carcinoma; ACA; adenocarcinoma.
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rates were broken down into two time periods, there was 
a difference. In 1989–2003, the incidence of all types of 
cervical cancer decreased, although nonsignificant for 
adenocarcinoma. During 2004–2013, the incidence of all 
cervical carcinomas remained stable. The trends in inci-
dence of invasive cervical carcinomas in the Netherlands 
as found by Bulk et al. and de Kok et al. [8, 9] were 
confirmed in this study. The same trends are found world-
wide [1, 4–7]. A possible explanation for this is the 
increased detection rate for CIN in the Netherlands, as 
found by Rozemeijer et al. [12] during 2000–2011. The 
authors contribute this increase to the implementation of 
liquid- based cytology, but also an increased cervical cancer 
risk, which was confirmed by this study.
The main goal of this study was to investigate the 
incidence rates of adenocarcinoma in situ (AIS) of the 
uterine cervix in 2004–2013. Crude rates were calculated 
per 100,000 person years, using the absolute incidence of 
invasive carcinomas from the national cancer registry and 
data concerning AIS retrieved from PALGA, combined 
with population data from Statistics Netherlands. The 
crude rates for adenocarcinoma calculated by this method 
Figure 2. Scatterplot of the European Standardized Rates of AIS in the 
years 2004–2013 with correlation lines. ACA r = 0.330 with P = 0.322/
AIS r = 0.951 with P = 0.000. ACA, adenocarcinoma; AIS, adenocarcinoma 
in situ.
year
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Table 2. EAPC 2004 to 2013, 95% confidence interval (95% CI) and 
P- value for ACA, AIS and AIS with (AIS+) and without (AIS- ) concomi-
tant CIN.
 EAPC (%) 95% CI (%) P-value
ACA 1.31 −0.66, 3.31 0.24
AIS 9.20 7.50, 10.92 0.00
AIS+ 10.96 8.38, 13.60 0.00
AIS- 6.93 5.06, 8.83 0.00
EAPC, estimated annual percentage change; CIN, cervical intraepithelial 
neoplasia; ACA, adenocarcinoma; AIS, adenocarcinoma in situ.
Figure 3. Crudes rates of adenocarcinoma in situ in the age categories 
25–29, 30–34, 35–39, and over 40 in the years 2004–2013 with fit line.
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Figure 4. Scatterplot of the European Standardized Rates of 
adenocarcinoma in situ with (AIS+) and without (AIS- ) concomitant CIN 
in the years 2004–2013. AIS + r = 0.934 with P = 0.000 / AIS- r = 0.928 
with P = 0.000. CIN, cervical intraepithelial neoplasia.
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showed only minor variance from the numbers retrieved 
from IKNL. From these crude rates, the European standard 
rates (ESR) per 100,000 women years were determined.
AIS of the uterine cervix is considered as a precancer-
ous lesion of invasive cervical adenocarcinoma. Convincing 
evidence includes (1) the fact that AIS is usually diagnosed 
in populations 10–20 years younger than those with inva-
sive adenocarcinoma, (2) AIS frequently coexists with 
invasive adenocarcinoma on histological specimens, (3) 
records of cases of untreated AIS that precede invasive 
adenocarcinoma, and lastly (4) the discovery of similar 
high- risk human papillomavirus (hrHPV) types in both 
AIS and adenocarcinoma [2]. Therefore, one would expect 
that timely identification of AIS would decrease the inci-
dence of invasive adenocarcinoma.
We found a total of 1678 cases of AIS between 2004 
and 2013. In this period, the incidence of AIS significantly 
increased. Compared to this, invasive adenocarcinoma 
showed a slight but nonsignificant increase. The increase 
in AIS was predominant in women in the 25–39 age 
groups. This finding is not in accordance with the trends 
found by van de Nieuwenhof et al.[10], who described 
a decrease in the adenocarcinoma in situ incidence with 
a stable adenocarcinoma incidence in the period of 1989–
2003. The decrease in AIS incidence, as found by them 
was predominantly in the age groups 15–29, 45–49, and 
over 60. However, their method of data retrieval concern-
ing AIS cases might have differed from the one used in 
this study. By using the Dutch national pathology database 
(PALGA) and scrutinizing all records with the specific 
terms mentioned as mentioned above, we are convinced 
that our dataset is more complete. This can partly explain 
the difference between this study and the study by van 
de Nieuwenhof [10].
In other countries worldwide, an increase in both the 
adenocarcinoma and adenocarcinoma in situ incidence 
was found [4, 7, 9]. This is comparable to the trends 
found by us in this study, so it seems there are other 
factors at hand.
There are several possible explanations for the increase 
in AIS incidence found in this study. A more systematic 
screening for and treatment of CIN could have led to 
the incidental detection of AIS since glandular cervical 
lesions are often associated with high- grade cervical 
intraepithelial neoplasia (CIN2- 3) [13–15], and these com-
bined lesions have higher percentages of hrHPV compared 
to glandular atypia and adenocarcinoma in situ not asso-
ciated with squamous lesions [13, 15]. In our study, more 
than half of AIS patients had concomitant CIN and we 
confirmed that the increase in AIS rates was stronger in 
AIS cases with concomitant CIN.
The association of human papilloma virus (HPV) and 
cervical squamous cell carcinoma is well known and causal 
in nature. Squamous cell carcinomas are preceded by CIN 
[16] and over 90% of carcinomas harbor hrHPV, with 
HPV type 16 and HPV type 18 as the most common 
subtypes, with an overall predominance of HPV type 16 
[17]. However, in endocervical columnar lesions, the role 
of hrHPV is less clear- cut, although adenocarcinoma and 
squamous cell carcinoma share many of the same risk 
factors with the exception of smoking [18]. HrHPV is 
detected in a majority of adenocarcinomas, with slightly 
lower frequencies, which vary between 70% and 98% [7, 
17, 19–24]. In adenocarcinoma (in situ), there is a pre-
dominance of HPV types 16, 18 [20, 25, 26], and 45 [24]. 
Furthermore, hrHPV incidence varies between adenocar-
cinoma subtypes, for instance, in minimal deviation adeno-
carcinoma, gastric type and clear cell adenocarcinomas, a 
significantly lower level of hrHPV infection was found 
[24, 25] or hrHPV was not detected at all [7, 20, 27, 28].
For AIS, the implementation of liquid- based cytology 
and the cytobrush could also have contributed to the 
increased incidence we found in this study, comparable 
to the results for CIN as found by Rozemeijer et al. [12]. 
Glandular lesions are often located deep in the endocervi-
cal canal and therefore more difficult to sample with the 
conventional Pap- smear tools. Furthermore, in conven-
tional Pap- smears, the cytological features of AIS are subtle 
and often show overlap with the cytological features of 
CIN. In liquid- based cytology, the sensitivity for glandular 
lesions is increased [29]. This together with a better 
understanding of morphology and etiology and therefore 
a higher awareness by pathologists of glandular lesions, 
could lead to improved recognition of glandular lesions. 
This higher awareness could also have ensured better 
co ding and reporting of AIS in the PALGA database. 
Furthermore, in 2007, hrHPV triaging was implemented 
in the Netherlands. This meant that the first repeat cyto-
logy after detection of a borderline lesion (ASC- US of 
LSIL) is combined with hrHPV testing. This could have 
led to the detection of more precursor lesions, for instance 
concomitant squamous and glandular lesions.
As stated by Rozemeijer et al. [12], another explanation 
could be a change in risk factors. In the Netherlands, 
the HPV16 antibody seroprevalence has increased during 
adolescence and shifted to younger ages [30]. This is 
probably due to a younger age at first intercourse. The 
same study also found a higher prevalence of HPV type 
18, which is, as mentioned above, the biggest contributor 
in cervical adenocarcinoma. The increasing HPV prevalence 
in the population is also reflected in increasing incidence 
rates of other HPV- related cancer types, such as anal and 
vulvar carcinoma [12]. However, it is too early to see 
any effects of HPV vaccination, since this was introduced 
in the Dutch Nationwide Immunisation Programme in 
2010 [31, 32].
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In the Netherlands, a nationwide screening program 
with the primary goal of lowering mortality and morbidity 
of cervical cancer by detecting and treating precancerous 
squamous cervical lesions is implemented. The Dutch 
nationwide screening program for cervical cancer invites 
women to participate at a 5 year interval which starts at 
age 30 and ends at age 60. In this study, most AIS lesions 
were detected around the ages when women were invited 
to take part in the screening program. The highest peak 
in incidence was around 19–30 years, which, when this 
group was further subdivided, could in majority be 
accounted for by 29- year- old women. Since women receive 
an invitation for screening in the year in which they turn 
30, this peak can be explained by participation in the 
national screening program. Since this screening is more 
effective in detecting squamous intraepithelial neoplasia, 
it would stand to reason that most cases of AIS which 
were detected through the screening program would have 
a concomitant CIN. This was confirmed in this study, 
since the group of women with both AIS and CIN was 
significantly larger than the group of women with AIS 
lacking concomitant CIN.
This effect of screening could also be seen in the inci-
dence levels of invasive cervical carcinomas. The incidence 
of all types of invasive cervical cancer showed two peaks 
(data not shown). The first peak was in the 35–39 year 
age group. This coincides with the second screening round 
in the Dutch nationwide screening program. The second 
peak was in the 70–74 year age group.
But despite the nationwide screening program in the 
Netherlands, there was an increase in AIS with stable 
rates of invasive adenocarcinoma. An increase in incidence 
of invasive adenocarcinomas as well as in situ adenocar-
cinomas has been shown in multiple countries worldwide, 
such as the Unites States, Korea, Sweden, and other 
European countries [1, 4, 7, 33]. However, presumably 
with adequate screening and treatment of the precursor 
lesion of adenocarcinoma, one would expect a decrease 
in the incidence of invasive adenocarcinoma. Therefore, 
an increase in AIS rate (or an increase in AIS detection) 
could lead to a subsequent drop in adenocarcinoma inci-
dence. This was not found in this study, and also other 
studies found the same phenomenon of cervical cancer 
screening seemingly failing to decrease adenocarcinoma 
incidence [7, 9, 31]. Theoretically, it could be that this 
effect is not yet visible, since it takes approximately 10 years 
for AIS to progress into invasive adenocarcinoma [2]. Or 
it is possible that part of the precursor lesions we are 
detecting would have shown regression on their own.
In conclusion, the trends in incidence rates of adeno-
carcinoma in situ and invasive carcinomas of the uterine 
cervix that are present worldwide are also found in the 
Netherlands. In the years 1989–2003, the incidence of all 
types of cervical cancer declined, while in 2004–2013, the 
incidence remained stable. This was accompanied by an 
increase in AIS incidence rates during 2004–2013, pre-
dominantly caused by cases of AIS with concomitant CIN.
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